{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T01:29:10Z","timestamp":1760318950368,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004371","name":"Tampereen Yliopisto","doi-asserted-by":"publisher","award":["TUT-RAE"],"award-info":[{"award-number":["TUT-RAE"]}],"id":[{"id":"10.13039\/501100004371","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>P2Y receptors belong to the large superfamily of G-protein-coupled receptors and play a crucial role in cell death and survival. P2Y1 receptor has been identified as a marker for prostate cancer (PCa). A previously unveiled selective P2Y1 receptor agonist, the indoline-derived HIC (1-(1-((2-hydroxy-5-nitrophenyl)(4-hydroxyphenyl)methyl)indoline-4-carbonitrile), induces a series of molecular and biological responses in PCa cells PC3 and DU145, but minimal toxicity to normal cells. Here, we evaluated the combinatorial effect of HIC with abiraterone acetate (AA) targeted on androgen receptor (AR) on the inhibition of PCa cells. Here, the presence of HIC and AA significantly inhibited cell proliferation of PC3 and DU145 cells with time-dependent manner as a synerfistic combination. Moreover, it was also shown that the anticancer and antimetastasis effects of the combinratorial drugs were noticed through a decrease in colony-forming ability, cell migration, and cell invasion. In addition, the HIC\u2009+\u2009AA induced apoptotic population of PCa cells as well as cell cycle arrest in G1 progression phase. In summary, these studies show that the combination of P2Y1 receptor agonist, HIC and AR inhibitor, AA, effectively improved the antitumor activity of each drug. Thus, the combinatorial model of HIC and AA should be a novel and promising therapeutic strategy for treating prostate cancer.<\/jats:p>","DOI":"10.1007\/s10495-022-01716-1","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T07:08:55Z","timestamp":1644217735000},"page":"283-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Hien Thi Thu","family":"Le","sequence":"first","affiliation":[]},{"given":"Akshaya","family":"Murugesan","sequence":"additional","affiliation":[]},{"given":"Nuno R.","family":"Candeias","sequence":"additional","affiliation":[]},{"given":"Thiyagarajan","family":"Ramesh","sequence":"additional","affiliation":[]},{"given":"Olli","family":"Yli-Harja","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4986-055X","authenticated-orcid":false,"given":"Meenakshisundaram","family":"Kandhavelu","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"1716_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CLEP.S16747","volume":"4","author":"MF Leitzmann","year":"2012","unstructured":"Leitzmann MF, Rohrmann S (2012) Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin. Epidemiol 4:1\u201311","journal-title":"Clin. Epidemiol"},{"key":"1716_CR2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1716_CR3","first-page":"A127","volume":"20","author":"JJ Ruterbusch","year":"2017","unstructured":"Ruterbusch JJ, Bylsma LC, Barlev A et al (2017) Bicalutamide treatment patterns in elderly prostate cancer patients: a historical cohort study using the surveillance, epidemiology and end results program (SEER)-medicare database. Val Heal 20(5):A127\u2013A128","journal-title":"Val Heal"},{"key":"1716_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1503954","author":"DE Rathkopf","year":"2018","unstructured":"Rathkopf DE, Scher HI (2018) Apalutamide for the treatment of prostate cancer. Expert Rev Anticancer Ther. https:\/\/doi.org\/10.1080\/14737140.2018.1503954","journal-title":"Expert Rev Anticancer Ther"},{"key":"1716_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1207506","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa1207506","journal-title":"N Engl J Med"},{"key":"1716_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1715546","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa1715546","journal-title":"N Engl J Med"},{"key":"1716_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70417-6","author":"CN Sternberg","year":"2014","unstructured":"Sternberg CN, Castellano D, Daugaard G et al (2014) Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(14)70417-6","journal-title":"Lancet Oncol"},{"issue":"34","key":"1716_CR8","first-page":"12182","volume":"105","author":"CA Heinlein","year":"2004","unstructured":"Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 105(34):12182\u201312187","journal-title":"Endocr Rev"},{"issue":"1","key":"1716_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","volume":"36","author":"ME Tan","year":"2015","unstructured":"Tan ME, Li J, Xu HE et al (2015) Androgen receptor: Structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin 36(1):3\u201323","journal-title":"Acta Pharmacol Sin"},{"key":"1716_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000000684","author":"AB Weiner","year":"2020","unstructured":"Weiner AB, Cohen JE, DeLancey JO et al (2020) Surgical versus medical castration for metastatic prostate cancer: use and overall survival in a National Cohort. J Urol. https:\/\/doi.org\/10.1097\/ju.0000000000000684","journal-title":"J Urol"},{"key":"1716_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.09.020","author":"R Garje","year":"2020","unstructured":"Garje R, Chennamadhavuni A, Mott SL et al (2020) Utilization and outcomes of surgical castration in comparison to medical castration in metastatic prostate cancer. Clin Genitourin Cancer. https:\/\/doi.org\/10.1016\/j.clgc.2019.09.020","journal-title":"Clin Genitourin Cancer"},{"issue":"49","key":"1716_CR12","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32(49):5501\u20135511","journal-title":"Oncogene"},{"key":"1716_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31161","author":"SK Pal","year":"2018","unstructured":"Pal SK, Patel J, He M et al (2018) Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). Cancer. https:\/\/doi.org\/10.1002\/cncr.31161","journal-title":"Cancer"},{"key":"1716_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-3-574","author":"F Bremmer","year":"2014","unstructured":"Bremmer F, Jarry H, Strau\u00df A et al (2014) Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC). J Korean Phys Soc. https:\/\/doi.org\/10.1186\/2193-1801-3-574","journal-title":"J Korean Phys Soc"},{"issue":"24","key":"1716_CR15","doi-asserted-by":"publisher","first-page":"6650","DOI":"10.1158\/1078-0432.CCR-13-2134","volume":"19","author":"PG Kluetz","year":"2013","unstructured":"Kluetz PG, Ning YM, Maher VE et al (2013) Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: US food and drug administration drug approval summary. Clin Cancer Res 19(24):6650\u20136656","journal-title":"Clin Cancer Res"},{"key":"1716_CR16","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.196","author":"DJ Bedoya","year":"2014","unstructured":"Bedoya DJ, Mitsiades N (2014) Expert Review of Anticancer Therapy Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Expert Rev Anticancer Ther. https:\/\/doi.org\/10.1586\/era.11.196","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"1716_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/1758834012458137","volume":"5","author":"J Amm","year":"2013","unstructured":"Amm J, Aragon Ching JB (2013) The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 5(1):25\u201340","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"1716_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/clpt.2011.275","volume":"91","author":"A Bryce","year":"2012","unstructured":"Bryce A, Ryan CJ (2012) Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Clin Pharmacol Ther 91(1):101\u2013108","journal-title":"Clin Pharmacol Ther"},{"key":"1716_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-00271-7","author":"RR McKay","year":"2020","unstructured":"McKay RR, Silver R, Bhak RH et al (2020) Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-020-00271-7","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1716_CR20","unstructured":"US Food and Drug Administration (2018) FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer. https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm596015.htm. Accessed 15 June 2020"},{"key":"1716_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.e17539","author":"QUAR Sipra","year":"2020","unstructured":"Sipra QUAR, Bin RI, Asghar N et al (2020) Treatment of metastatic castration sensitive prostate cancer (mCSPC) by disease volume: A systematic review and a meta-analysis. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2020.38.15_suppl.e17539","journal-title":"J Clin Oncol"},{"key":"1716_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-019-01622-5","author":"M Fragni","year":"2019","unstructured":"Fragni M, Galli D, Nardini M et al (2019) Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-019-01622-5","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1716_CR23","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.3274","author":"H Grossebrummel","year":"2016","unstructured":"Grossebrummel H, Peter T, Mandelkow R et al (2016) Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways. Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2015.3274","journal-title":"Int J Oncol"},{"key":"1716_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.484","author":"WH Li","year":"2013","unstructured":"Li WH, Qiu Y, Zhang HQ et al (2013) P2Y2 receptor promotes cell invasion and metastasis in prostate cancer cells. Br J Cancer. https:\/\/doi.org\/10.1038\/bjc.2013.484","journal-title":"Br J Cancer"},{"key":"1716_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07293.x","author":"M Shabbir","year":"2008","unstructured":"Shabbir M, Ryten M, Thompson C et al (2008) Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer. BJU Int. https:\/\/doi.org\/10.1111\/j.1464-410X.2007.07293.x","journal-title":"BJU Int"},{"key":"1716_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.05.013","author":"Q Wei","year":"2011","unstructured":"Wei Q, Costanzi S, Liu QZ et al (2011) Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells. Biochem Pharmacol. https:\/\/doi.org\/10.1016\/j.bcp.2011.05.013","journal-title":"Biochem Pharmacol"},{"key":"1716_CR27","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.0640","author":"R Janssens","year":"1996","unstructured":"Janssens R, Communi D, Pirotton S et al (1996) Cloning and tissue distribution of the human P2Y1 receptor. Biochem Biophys Res Commun. https:\/\/doi.org\/10.1006\/bbrc.1996.0640","journal-title":"Biochem Biophys Res Commun"},{"key":"1716_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55194-8","author":"HTT Le","year":"2019","unstructured":"Le HTT, Rimpilainen T, Konda Mani S et al (2019) Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-019-55194-8","journal-title":"Sci Rep"},{"key":"1716_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijbiomac.2021.08.103","volume":"189","author":"HTT Le","year":"2021","unstructured":"Le HTT, Murugesan A, Ramesh T et al (2021) Molecular interaction of HIC, an agonist of P2Y1 receptor, and its role in prostate cancer apoptosis. Int J Biol Macromol 189:142\u2013150. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.08.103","journal-title":"Int J Biol Macromol"},{"issue":"21","key":"1716_CR30","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.4155\/fmc-2021-0159","volume":"13","author":"HTT Le","year":"2021","unstructured":"Le HTT, Murugesan A, Candeias NR et al (2021) Functional characterization of HIC, a P2Y1 agonist, as a p53 stabilizer for prostate cancer cell death induction. Futur Med Che 13(21):1845\u20131864","journal-title":"Futur Med Che"},{"issue":"3","key":"1716_CR31","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621\u2013681","journal-title":"Pharmacol Rev"},{"key":"1716_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/0065-2571(84)90007-4","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. https:\/\/doi.org\/10.1016\/0065-2571(84)90007-4","journal-title":"Adv Enzyme Regul"},{"key":"1716_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.synres.2018.04.001","volume":"7","author":"TC Chou","year":"2018","unstructured":"Chou TC (2018) The combination index (CI < 1) as the definition of synergism and of synergy claims. Synergy 7:49\u201350","journal-title":"Synergy"},{"key":"1716_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2005970","author":"C McQuin","year":"2018","unstructured":"McQuin C, Goodman A, Chernyshev V et al (2018) Cell profiler 3.0: next-generation image processing for biology. PLoS Biol. https:\/\/doi.org\/10.1371\/journal.pbio.2005970","journal-title":"PLoS Biol"},{"key":"1716_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2121-14-32","author":"M Brentnall","year":"2013","unstructured":"Brentnall M, Rodriguez-Menocal L, De Guevara RL et al (2013) Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. https:\/\/doi.org\/10.1186\/1471-2121-14-32","journal-title":"BMC Cell Biol"},{"key":"1716_CR36","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2021-0159","author":"HT Le Thu","year":"2021","unstructured":"Le Thu HT, Murugesan A, Candeias NR et al (2021) Functional characterization of HIC, a P2Y1 agonist, as a p53 stabilizer for prostate cancer cell death induction. Future Med Chem. https:\/\/doi.org\/10.4155\/fmc-2021-0159","journal-title":"Future Med Chem"},{"key":"1716_CR37","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1016\/j.bbamcr.2016.09.012","volume":"1863","author":"M Redza-Dutordoir","year":"2016","unstructured":"Redza-Dutordoir M, Averill-Bates DA (2016) Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta Mol Cell Res 1863:2977\u20132992","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1716_CR38","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009616228304","author":"HU Simon","year":"2000","unstructured":"Simon HU, Haj-Yehia A, Levi-Schaffer F (2000) Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. https:\/\/doi.org\/10.1023\/A:1009616228304","journal-title":"Apoptosis"},{"key":"1716_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-9084(02)01369-X","author":"C Fleury","year":"2002","unstructured":"Fleury C, Mignotte B, Vayssi\u00e8re JL (2002) Mitochondrial reactive oxygen species in cell death signaling. Biochimie. https:\/\/doi.org\/10.1016\/S0300-9084(02)01369-X","journal-title":"Biochimie"},{"key":"1716_CR40","doi-asserted-by":"publisher","DOI":"10.4161\/psb.3.10.5908","author":"A Feher","year":"2008","unstructured":"Feher A, \u00d6tv\u00f6s K, Pasternak TP, Pettk\u00f3-Szandtner A (2008) The involvement of reactive oxygen species (ROS) in the cell cycle activation (G 0 -to-G 1 transition) of plant cells. Plant Signal Behav. https:\/\/doi.org\/10.4161\/psb.3.10.5908","journal-title":"Plant Signal Behav"},{"issue":"3","key":"1716_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1046\/j.1365-2184.2003.00267.x","volume":"36","author":"K Vermeulen","year":"2003","unstructured":"Vermeulen K, Berneman ZN, Van Bockstaele DR (2003) Cell cycle and apoptosis. Cell Prolif 36(3):165\u2013175","journal-title":"Cell Prolif"},{"key":"1716_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495\u2013516. https:\/\/doi.org\/10.1080\/01926230701320337","journal-title":"Toxicol Pathol"},{"key":"1716_CR43","unstructured":"Martin T, Ye L, Sanders A, et al (2014) Cancer invasion and metastasis: molecular and cellular perspective. Metastatic Cancer Clin Biol Perspect"},{"key":"1716_CR44","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2017.4178","author":"A Ju","year":"2018","unstructured":"Ju A, Cho YC, Kim BR et al (2018) Anticancer effects of methanol extract of Myrmecodia platytyrea Becc leaves against human hepatocellular carcinoma cells via inhibition of ERK and STAT3 signaling pathways. Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2017.4178","journal-title":"Int J Oncol"},{"key":"1716_CR45","doi-asserted-by":"publisher","first-page":"839","DOI":"10.4161\/cbt.10.9.13738","volume":"10","author":"T Bagnyukova","year":"2010","unstructured":"Bagnyukova T, Serebriiskii IG, Zhou Y et al (2010) Chemotherapy and signaling: how can targeted therapies supercharge cytotoxic agents? Cancer Biol Ther 10:839\u2013853","journal-title":"Cancer Biol Ther"},{"key":"1716_CR46","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/cancers3010994","volume":"3","author":"T Ozaki","year":"2011","unstructured":"Ozaki T, Nakagawara A (2011) Role of p53 in cell death and human cancers. Cancers (Basel) 3:994\u20131013","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1716_CR47","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.3390\/ijms19123999","volume":"19","author":"L Lossi","year":"2018","unstructured":"Lossi L, Castagna C, Merighi A (2018) Caspase-3 mediated cell death in the normal development of the mammalian cerebellum. Int J Mol Sci 19(12):3999","journal-title":"Int J Mol Sci"},{"key":"1716_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/sj.cr.7290049","volume":"10","author":"JH Zhang","year":"2000","unstructured":"Zhang JH, Xu M (2000) DNA fragmentation in apoptosis. Cell Res 10:205\u2013211","journal-title":"Cell Res"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-022-01716-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-022-01716-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-022-01716-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T06:27:37Z","timestamp":1647930457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-022-01716-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":48,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1716"],"URL":"https:\/\/doi.org\/10.1007\/s10495-022-01716-1","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"type":"print","value":"1360-8185"},{"type":"electronic","value":"1573-675X"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"24 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}